AOC 1001 is based on Avidity’s Antibody Oligonucleotide Conjugates (AOCs™) platform, designed to treat diseases of high unmet need by combining the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide therapies . . .
Home Drug Discovery Antibodies RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision

- Drug Discovery
- Antibodies
- Antibody Drug Conjugates
- Cardiovascular Disease
- Therapeutics
- Cardiovascular Drugs
- OMICs
- DNA
- GEN Edge
- Immunology
- Monoclonal Antibodies
- Musculoskeletal Disorders
- Oligonucleotides
RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision
Avidity Biosciences plans to enter the clinic with its first in a new class of oligonucleotide-based treatments this year. The company will study its lead pipeline candidate, AOC 1001, in a Phase I/II trial in adults with myotonic dystrophy type 1 (DM1), set to start in the second half of the year. [Christoph Burgstedt / iStock / Getty Images Plus]